PYC Advances Clinical Program for Genetic Kidney Disease Treatment

PYC Therapeutics (ASX: PYC) has received the green light to proceed to the next stage of its clinical development program targeting Polycystic Kidney Disease (PKD), a major step for the company’s lead drug candidate, PYC-003. The announcement, released to the ASX on 7 July 2025, confirms approval from the Safety Review Committee (SRC) to escalate dosing and commence patient enrolment in the next phase of the trial.

The drug, PYC-003, is being tested in a Phase 1a Single Ascending Dose (SAD) study that is divided into two parts: Part A in healthy volunteers, and Part B in patients with PKD. With the SRC now satisfied with safety data from the first two cohorts in Part A, the trial will progress to cohort 3 and begin enrolling PKD patients in Part B.

The move into patient dosing is a critical milestone, not just for PYC’s clinical ambitions, but for the broader RNA therapeutics field. PYC-003 is designed to target the underlying genetic cause of PKD—one of the most common life-threatening inherited disorders, for which no approved treatment currently exists.

CEO Dr Rohan Hockings called the safety clearance “an important milestone,” noting that the dose used in cohort 2 is believed to be at the upper end of the anticipated efficacy range in humans based on pre-clinical models. Establishing safety at this dose lays the groundwork for advancing to pivotal trials.

Following the current Phase 1a study, the company will initiate a multiple ascending dose (MAD) study, which includes repeat dosing and an evaluation of the optimal regimen for patients. This open-label MAD trial will run in parallel with a Phase 1b randomised controlled trial to assess safety and early efficacy, setting the stage for a future registrational Phase 2/3 study.

The overall trial design reflects PYC’s strategy to compress timelines by integrating early clinical development stages, a common tactic among RNA-based drug developers. If successful, PYC-003 could proceed to late-stage development as early as 2026.

PYC Therapeutics is one of only a handful of ASX-listed biotech firms developing RNA therapies. Leveraging a proprietary drug delivery platform, the company aims to improve potency and precision in treating monogenic diseases—those caused by mutations in a single gene. These diseases represent a sweet spot for RNA drug developers due to their well-defined genetic targets and higher probability of clinical success.

With multiple programs in its pipeline, PYC is positioning itself as a leader in the emerging field of precision RNA medicine. The progression of PYC-003 into PKD patient dosing is a tangible validation of its approach and puts the company firmly on the radar for investors tracking clinical-stage biotech plays on the ASX.